Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2
- PMID: 6290390
- PMCID: PMC347658
- DOI: 10.1128/iai.37.3.1132-1137.1982
Protection against lethal challenge of BALB/c mice by passive transfer of monoclonal antibodies to five glycoproteins of herpes simplex virus type 2
Abstract
Monoclonal antibodies secreted by six hybridomas and recognizing antigenic sites on glycoproteins gC, gAB, gD, gE, and gF of herpes simplex virus type 2 were examined for their ability to protect BALB/c mice from lethal infection by the virus. Administration of monoclonal antibodies to individual glycoproteins intraperitoneally 3 h before footpad challenge with 10 times the 50% lethal dose of virus protected between 35 and 75% of the mice, except for one of two monoclonal antibodies recognizing antigens on gC. The antibodies did not neutralize virus in vitro and protected A/J mice deficient in the fifth component of complement as efficiently as complement-sufficient BALB/c mice. A good correlation was found between protection and titers of monoclonal antibodies assessed by antibody-dependent cell-mediated cytolysis. The results indicate that any of the glycoproteins can serve as antigens for a protective immune response. In addition, the data are compatible with protection being mediated by an antibody-dependent cell-mediated cytolysis mechanism.
Similar articles
-
Use of monoclonal antibody directed against herpes simplex virus glycoproteins to protect mice against acute virus-induced neurological disease.Infect Immun. 1981 Oct;34(1):192-9. doi: 10.1128/iai.34.1.192-199.1981. Infect Immun. 1981. PMID: 6271681 Free PMC article.
-
Herpes simplex virus antigens and antibodies: a survey of studies based on quantitative immunoelectrophoresis.Rev Infect Dis. 1980 Nov-Dec;2(6):899-913. doi: 10.1093/clinids/2.6.899. Rev Infect Dis. 1980. PMID: 6164087 Review.
-
Helper T cells induced by an immunopurified herpes simplex virus type I (HSV-I) 115 kilodalton glycoprotein (gB) protect mice against HSV-I infection.J Exp Med. 1985 Oct 1;162(4):1304-18. doi: 10.1084/jem.162.4.1304. J Exp Med. 1985. PMID: 2995536 Free PMC article.
-
Purification of herpes simplex virus glycoproteins B and C using monoclonal antibodies and their ability to protect mice against lethal challenge.J Gen Virol. 1985 May;66 ( Pt 5):1073-85. doi: 10.1099/0022-1317-66-5-1073. J Gen Virol. 1985. PMID: 2582080
-
The mouse model and understanding immunity to herpes simplex virus.Rev Infect Dis. 1991 Nov-Dec;13 Suppl 11:S935-45. doi: 10.1093/clind/13.supplement_11.s935. Rev Infect Dis. 1991. PMID: 1664131 Review.
Cited by
-
Human Antibodies against Herpes Simplex Virus 2 Glycoprotein G Do Not Neutralize but Mediate Antibody-Dependent Cellular Cytotoxicity.Antibodies (Basel). 2024 May 11;13(2):40. doi: 10.3390/antib13020040. Antibodies (Basel). 2024. PMID: 38804308 Free PMC article.
-
Effector functions are required for broad and potent protection of neonatal mice with antibodies targeting HSV glycoprotein D.Cell Rep Med. 2024 Feb 20;5(2):101417. doi: 10.1016/j.xcrm.2024.101417. Epub 2024 Feb 12. Cell Rep Med. 2024. PMID: 38350452 Free PMC article.
-
Protective mechanisms of nonneutralizing antiviral antibodies.PLoS Pathog. 2023 Oct 5;19(10):e1011670. doi: 10.1371/journal.ppat.1011670. eCollection 2023 Oct. PLoS Pathog. 2023. PMID: 37796829 Free PMC article. Review.
-
Monoclonal antibody therapy of herpes simplex virus: An opportunity to decrease congenital and perinatal infections.Front Immunol. 2022 Aug 9;13:959603. doi: 10.3389/fimmu.2022.959603. eCollection 2022. Front Immunol. 2022. PMID: 36016956 Free PMC article. Review.
-
Inducing broad-based immunity against viruses with pandemic potential.Immunity. 2022 May 10;55(5):738-748. doi: 10.1016/j.immuni.2022.04.010. Immunity. 2022. PMID: 35545026 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous